文献类型：期刊文献

英文题名：Therapeutic potential of targeting kynurenine pathway in neurodegenerative diseases

作者：Shen, Hualiang[1,2];Xu, Xinde[3];Bai, Yalong[3];Wang, Xiaoping[3];Wu, Yibin[2];Zhong, Jia[2];Wu, Qiyi[2];Luo, Yanjuan[1,2];Shang, Tianbo[1,2];Shen, Runpu[1,2];Xi, Meiyang[1,2];Sun, Haopeng[4]

机构：[1]Shaoxing Univ, Zhejiang Engn Res Ctr Fat soluble Vitamin, Shaoxing 312000, Peoples R China;[2]Shaoxing Univ, Coll Chem & Chem Engn, Shaoxing 312000, Peoples R China;[3]Zhejiang Med Co Ltd, Shaoxing 312500, Peoples R China;[4]China Pharmaceut Univ, Dept Med Chem, Nanjing 210009, Peoples R China

年份：2023

卷号：251

外文期刊名：EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

收录：SCI-EXPANDED(收录号：WOS:001004399300001)、、Scopus(收录号：2-s2.0-85149721337)、WOS

基金：The authors greatly acknowledge the support from the Zhejiang Province Basic Public Welfare Research Program (No. LGF20H300004) and the grants of National Natural Science Foundation of China (No. 22278270) .

语种：英文

外文关键词：Neurodegenerative diseases; Kynurenine pathway; Neuroprotective effects

外文摘要：Kynurenine pathway (KP), the primary pathway of L-tryptophan (Trp) metabolism in mammals, contains several neuroactive metabolites such as kynurenic acid (KA) and quinolinic acid (QA). Its imbalance involved in aging and neurodegenerative diseases (NDs) has attracted much interest in therapeutically targeting KP enzymes and KP metabolite-associated receptors, especially kynurenine monooxygenase (KMO). Currently, many agents have been discovered with significant improvement in animal models but only one aryl hydrocarbon receptor (AHR) agonist 30 (laquinimod) has entered clinical trials for treating Huntington's disease (HD). In this review, we describe neuroactive KP metabolites, discuss the dysregulation of KP in aging and NDs and summarize the development of KP regulators in preclinical and clinical studies, offering an outlook of targeting KP for NDs treatment in future.